5-(2-hydroxy-5-methylphenyl)-1-methylpyrazole | 123532-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(2-hydroxy-5-methylphenyl)-1-methylpyrazole
• 英文别名: 4-Methyl-2-(1-methyl-1H-pyrazol-5-yl)phenol；4-methyl-2-(2-methylpyrazol-3-yl)phenol
• CAS: 123532-23-0
• 化学式: C₁₁H₁₂N₂O
• 分子量: 188.229
• InChiKey: PPPYEAUMUZGOKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  水合 6-甲基色酮 在 吡啶 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 5-(2-hydroxy-5-methylphenyl)-1-methylpyrazole
  参考文献：
  名称：

  Nawrot-Modranka, Jolanta; Kostka, Krzysztof, Polish Journal of Chemistry, 1988, vol. 62, # 4-6, p. 417 - 426

  摘要：

  DOI：

文献信息

• CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR
  申请人：Gharbaoui Tawfik

  公开号：US20100234380A1

  公开（公告）日：2010-09-16

  The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HT 2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HT 2A serotonin receptor modulators, compositions thereof and methods of using the same.

  本发明涉及制备式（I）的苯基吡唑及其盐和药物组合物的过程，它们可用作5-HT2A 5-羟色胺受体活性的调节剂。本发明还涉及用于该过程的中间体及其制备方法。本发明还涉及5-HT2A 5-羟色胺受体调节剂的晶体形式、其组合物及其使用方法。
• 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：TEEGARDEN BRADLEY

  公开号：US20130237540A1

  公开（公告）日：2013-09-12

  The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及公式(Ia)的某些3-苯基吡唑衍生物及其药物组成物，可调节5-HT2A血清素受体的活性。该化合物及其药物组成物适用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、心房颤动、减少血栓形成的风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、器质性或非器质性精神病、精神病、急性精神分裂症、慢性精神分裂症、非特异性精神分裂症及相关疾病以及睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物分别或一起给予的联合治疗5-HT2A血清素受体介导的疾病的方法。
• NAWROT-MODRANKA, JOLANTA;KOSTKA, KRZYSZTOF, POL. J. CHEM., 62,(1988) N-6, C. 417-426
  作者：NAWROT-MODRANKA, JOLANTA、KOSTKA, KRZYSZTOF

  DOI：——

  日期：——
• CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US20180186748A1

  公开（公告）日：2018-07-05

  The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HT 2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HT 2A serotonin receptor modulators, compositions thereof and methods of using the same.
• US8481535B2
  申请人：——

  公开号：US8481535B2

  公开（公告）日：2013-07-09